Overview

Safety and Efficacy of Aliskiren on the Progression of Atherosclerosis in Coronary Artery Disease Patients

Status:
Completed
Trial end date:
2013-01-01
Target enrollment:
Participant gender:
Summary
The study will assess the change in coronary atherosclerotic disease as determined by intravascular ultrasound (IVUS) for aliskiren compared to placebo when given in addition to standard therapy in patients with coronary artery disease (CAD) and a blood pressure in the pre-hypertensive range.
Phase:
Phase 3
Details
Lead Sponsor:
Novartis Pharmaceuticals
Collaborator:
The Cleveland Clinic